"Isoniazid Preventive Therapy in Areas of High Isoniazid Resistance."

According to the authors' abstract of an article published in Archives of Internal Medicine, "Background: Previous decision analyses of isoniazid preventive therapy for low-risk tuberculin reactors aged 20 to 34 years have not accounted for the recently increased isoniazid resistance rate. Drug resistance trends could also affect the decision to use isoniazid preventive therapy for patients with recent conversion of tuberculin skin tests who are seronegative for human immunodeficiency virus. Methods: A decision analysis was performed with a Markov simulation to assess the difference in life expectancy between those who receive isoniazid preventive therapy and those who...

Want to see the full article?

• Purchase this article for only $3.00